Linked Life Data

17603402

Source:http://linkedlifedata.com/resource/pubmed/id/17603402

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
7
pubmed:dateCreated
2007-7-2
pubmed:abstractText
Selective serotonin reuptake inhibitors are considered the most effective and well-established pharmacotherapy for the treatment of obsessive-compulsive disorder (OCD), a chronic and disabling condition. However, approximately 40% of patients do not have a significant improvement, suggesting that new medications are needed. This study was designed to investigate the treatment response to escitalopram in OCD patients.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
1092-8529
pubmed:author
pubmed:issnType
Print
pubmed:volume
12
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
519-24
pubmed:meshHeading
pubmed:year
2007
pubmed:articleTitle
Obsessive-compulsive disorder: an open-label pilot trial of escitalopram.
pubmed:affiliation
Department of Psychiatry, Federal University of Bahia, Brazil.
pubmed:publicationType
Journal Article, Clinical Trial, Research Support, Non-U.S. Gov't